Immunotherapy for metastatic solid cancers

Turcotte, Simon; Rosenberg, Steven A.

doi:10.1016/j.yasu.2011.04.003

Cited by 81Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

Immunotherapy for metastatic solid cancers

Open access

Turcotte, Simon, Rosenberg, Steven A.·2011·Advances in Surgery

DOI 10.1016/j.yasu.2011.04.003PMC PMC3578602

Open this paper in CoChat — free account

Abstract

After decades of research on solid tumor immunology, immunotherapy has shown effectiveness in patients with metastatic solid cancers. Immune modulators such as IL-2 and anti-CTLA-4 can mediate tumor regression in patients with metastatic melanoma and renal cancer, two tumor types that appear exceptional in their ability to spontaneously harbor endogenous antitumor immune cells. The responses can be long lasting, but the number of patients who benefit from these molecules remains limited. Combinations of these agents with cytotoxic and biologic agents are being investigated as a means to increase response rates and in an attempt to broaden application to other cancer types. Rare responses to cancer vaccines suggest that a better understanding of the underlying biology and mechanism of actions may lead to wider application in the future. The most effective form of immunotherapy thus far, capable of eradicating large tumor burdens in melanoma patients, is the ACT of TIL given to patients after lymphodepletion. As an alternative, lymphocytes engineered to recognize tumor-associated antigens can be safely infused to patients. With this approach, tumor regression is now being reported for cancers other than melanoma, but success remains constrained by the identification of antigens expressed with high specificity by cancer cells and not by normal tissues.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.yasu.2011.04.003

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Immunotherapies have shown promising results for reducing metastasis in melanoma or kidney cancer patients.
“Recently, immunotherapies have shown promising results for reducing metastasis in melanoma or kidney cancer patients[1, 2].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [1]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548 · see citing works
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,956 · see citing works
Self-citation
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · see citing works
Self-citation
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works
Self-citation
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature reviews. Immunology · doi:10.1038/nri2785 · Cited by 2,443 · see citing works
Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · see citing works
Self-citation
A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Rosenberg, S. A., Spiess, P. J., & Lafrenière, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,888 · see citing works
Self-citation
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C.-H., Morgan, R. A., & Dudley, M. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2355 · Cited by 1,654 · see citing works
Self-citation
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works
Self-citation
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Clemens, S. A. C., & Dubin, G. O. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,629 · see citing works
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625 · see citing works
Self-citation
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587 · see citing works
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · see citing works
Self-citation
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works
Self-citation
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 <sup>+</sup> T lymphocytes are prognostic factors of human ovarian cancer
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · see citing works
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · see citing works
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Royal, R. E., Levy, C. L., Turner, K. M., Mathur, A., Hughes, M. S., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C.-H., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,266 · see citing works
Self-citation
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254 · see citing works
Self-citation
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Chen, Y., Scanlan, M. J., Şahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M. G., & Old, L. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1914 · Cited by 1,247 · see citing works
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Pulè, M. A., Savoldo, B., Myers, G. D., Rössig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195 · see citing works
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025 · see citing works
Self-citation
Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915 · see citing works
Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 872 · see citing works
Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869 · see citing works
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 791 · see citing works
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697 · see citing works
Self-citation
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 687 · see citing works
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
Eggermont, A. M. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H. J., Marsden, J. R., Punt, C. J. A., Salès, F., Gore, M. E., MacKie, R. M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 639 · see citing works
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 634 · see citing works
Tumour immunity: effector response to tumour and role of the microenvironment
Mantovani, A., Romero, P. J., Palucka, A. K., & Marincola, F. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60241-x · Cited by 536 · see citing works
Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2
Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 486 · see citing works
Self-citation
A listing of human tumor antigens recognized by T cells: March 2004 update
Novellino, L., Castelli, C., & Parmiani, G. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0560-6 · Cited by 469 · see citing works
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
Besser, M. J., Shapira‐Frommer, R., Treves, A. J., Zippel, D. B., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462 · see citing works
Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Sharfman, W., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U. S., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 460 · see citing works
Self-citation
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Butts, C. A., Murray, N., Maksymiuk, A. W., Goss, G. D., Marshall, E., Soulières, D., Cormier, Y. F., Ellis, P., Price, A., Sawhney, R. P. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 427 · see citing works
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L. H., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 404 · see citing works
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Blood · doi:10.1182/blood-2010-01-265041 · Cited by 392 · see citing works
Self-citation
Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions
Robbins, P. F., Li, Y. F., El‐Gamil, M., Zhao, Y., Wargo, J. A., Zheng, Z., Xu, H., Morgan, R. A., Feldman, S. A., Johnson, L. A., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6116 · Cited by 385 · see citing works
Self-citation
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
Brentjens, R. J., Yeh, R., Bernal, Y. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.31 · Cited by 380 · see citing works
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
Lamers, C., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 370 · see citing works
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 335 · see citing works
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Dudley, M. E., Gross, C. A., Langhan, M. M., García, M. R., Sherry, R. M., Yang, J. C.-H., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1297 · Cited by 313 · see citing works
Self-citation
Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
Chung, K. Y., Gore, I., Fong, L. H., Venook, A. P., Beck, S. B., Dorazio, P., Criscitiello, P. J., Healey, D. I., Huang, B., Gómez-Navarro, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3994 · Cited by 307 · see citing works
Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma
Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E., & Rosenberg, S. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3477 · Cited by 302 · see citing works
Self-citation
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271 · see citing works
Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions
Hughes, M., Yu, Y., Dudley, M., Zheng, Z.-L., Robbins, P., Li, Y. F., Wunderlich, J., Hawley, R., Moayeri, M., Rosenberg, S., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.457 · Cited by 261 · see citing works
Self-citation
Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
Testori, A., Richards, J. M., Whitman, E. D., Mann, G. B., Lutzky, J., Camacho, L. H., Parmiani, G., Tosti, G., Kirkwood, J. M., Hoos, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9941 · Cited by 257 · see citing works
Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Kerkar, S. P., Muranski, P. J., Kaiser, A., Boni, A., Sanchez-Perez, L. A., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254 · see citing works
Self-citation
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43490 · Cited by 253 · see citing works
Self-citation
Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
Stein, W. D., Gulley, J. L., Schlom, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1762 · Cited by 248 · see citing works
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
Kirkwood, J. M., Lorigan, P. C., Hersey, P., Hauschild, A., Robert, C., McDermott, D. F., Marshall, M. A., Gómez-Navarro, J., Liang, J. Q., & Bulanhagui, C. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2033 · Cited by 241 · see citing works
Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
Gulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228 · see citing works
Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
Giaccone, G., Debruyne, C., Felip, E., Chapman, P. B., Grant, S. C., Millward, M., Thiberville, L., DʼAddario, G., Coens, C., Rome, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.186 · Cited by 223 · see citing works
Myeloid-Derived Suppressor Cells in Human Cancer
Nagaraj, S., & Gabrilovich, D. I. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3358 · Cited by 222 · see citing works
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Amato, R. J., Hawkins, R. E., Kaufman, H. L., Thompson, J. A., Tomczak, P., Szczylik, C. A., McDonald, M., Eastty, S., Shingler, W. H., de Belin, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2082 · Cited by 199 · see citing works
Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer
Vinageras, E. N., de la Torre, A., Rodríguez, M. O., Ferrer, M. C., Cortada, I. B., del Pino, M. M., Abreu, D. A., Brooks, S. A., Rives, R., Carrillo, C. D. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5980 · Cited by 197 · see citing works
Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines
Zhao, Y., Zheng, Z., Robbins, P. F., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4415 · Cited by 191 · see citing works
A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer
Chinnasamy, N., Wargo, J. A., Yu, Z., Rao, M., Frankel, T. L., Riley, J. P., Hong, J. J., Parkhurst, M. R., Feldman, S. A., Schrump, D. S., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001775 · Cited by 161 · see citing works
Self-citation
Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
Madan, R. A., Gulley, J. L., Fojo, T., & Dahut, W. L. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0129 · Cited by 140 · see citing works
Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials
Wheatley, K., Ives, N. J., Eggermont, A. M. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8526 · Cited by 139 · see citing works
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
Robert, C., & Ghiringhelli, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0028 · Cited by 128 · see citing works
New Therapies for Castration-Resistant Prostate Cancer
Longo, D. L. (2010) · New England Journal of Medicine · doi:10.1056/nejme1006300 · Cited by 127 · see citing works
Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study
Petrella, T. M., Tozer, R. G., Bélanger, K., Savage, K. J. J., Wong, R., Smylie, M., Kamel‐Reid, S., Tron, V. A., Chen, B. E., Hunder, N. N. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0655 · Cited by 126 · see citing works
Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells
Parkhurst, M. R., Joo, J. S., Riley, J. P., Yu, Z., Li, Y., Robbins, P. F., & Rosenberg, S. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1638 · Cited by 122 · see citing works
Self-citation
Prevention and Treatment of Papillomavirus-Related Cancers Through Immunization
Frazer, I. H., Leggatt, G. R., & Mattarollo, S. R. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101308 · Cited by 120 · see citing works
Breast cancer care in older women
Silliman, R. A., Dukes, K. A., SULLIVAN, L. M., & Kaplan, S. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980815)83:4 · Cited by 119 · see citing works
Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response
Rosenberg, S. A., Yang, J., White, D. E., & Steinberg, S. M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68669-7 · Cited by 116 · see citing works
Self-citation
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Schwartzentruber, D. J., Lawson, D. J., Richards, J. M., Conry, R. M., Miller, D. M., Triesman, J., Gailani, F., Riley, L., Vena, D. A., & Hwu, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra9011 · Cited by 83 · see citing works
Safer CARS
Heslop, H. E. (2010) · Molecular Therapy · doi:10.1038/mt.2010.42 · Cited by 70 · see citing works
CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues
Phan, G. Q., Weber, J. S., & Sondak, V. K. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0104-y · Cited by 58 · see citing works
Therapeutic Vaccines for Melanoma
Faries, M. B., & Morton, D. L. (2005) · BioDrugs · doi:10.2165/00063030-200519040-00004 · Cited by 31 · see citing works
Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine
Hersh, E. M., Weber, J. S., Powderly, J. D., Khan, K. D., Pavlick, A. C., Samlowski, W. E., O'Day, S. J., Nichol, G., Yellin, M. J., & Cramner, L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9022 · Cited by 30 · see citing works
Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma.
Prieto, P. A., Yang, J., Sherry, R. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8544 · Cited by 20 · see citing works
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Schwartzentruber, D. J., Lawson, D. J., Richards, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18s.cra9011 · Cited by 14 · see citing works
Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM).
Petrella, T. M., Tozer, R. G., Bélanger, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8507 · Cited by 8 · see citing works

Flagged first, then by citations

Research works printed but not linked: 2

[42]Higano C aad F omer B A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) ASCO Genitourinary Cancers Symposium 2009 Abstract No. LBA150
[43]Small EJ Demkow T Gerritsen WR A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) ASCO Genitourinary Cancers Symposium 2009 Abstract No. 7

Sorted by citations

Microfluidics: A New Tool for Modeling Cancer–Immune Interactions
Boussommier-Calleja, A., Li, R., Chen, M. B., Wong, S. C., & Kamm, R. D. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.12.003 · Cited by 224 · see citing works
“Recently, immunotherapies have shown promising results for reducing metastasis in melanoma or kidney cancer patients[1, 2].”
Background
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126 · see citing works
Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy
Turcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300538 · Cited by 107 · see citing works
Self-citation

Carcinogenic Effects of Steroids
Bischoff, F. (1969) · Advances in lipid research · doi:10.1016/b978-0-12-024907-7.50011-7 · Cited by 100 · see citing works
Effect of Metazoa on Proportion of Physiologically Active Bacteria.
Fujimoto, N., Asuka, I., Suzuki, M., et al. (1999) · Japanese Journal of Water Treatment Biology · doi:10.2521/jswtb.35.279 · Cited by 1 · see citing works
Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing
Yamamoto, S., Urano, K., & Nomura, T. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00341-5 · Cited by 34 · see citing works
The mutagenicity of 45 nitrosamines in Salmonella typhimurium
Andrews, A. W., & Lijinsky, W. (1981) · Teratogenesis Carcinogenesis and Mutagenesis · doi:10.1002/tcm.1770010306 · Cited by 35 · see citing works
The influence of the extent of target organs on sensitivities of methods for screening rodent carcinogens
Fu, Z.-D., Chen, W., Gu, L.-J., et al. (1995) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(95)00056-o · Cited by 3 · see citing works

Authors: Turcotte, S., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
Corresponding author: Rosenberg, Steven A.
ORCID: Turcotte, Simon
Rosenberg, Steven A.
Venue: Advances in Surgery
Publisher: Elsevier BV
Published: 2011-09
Volume: 45
Issue: 1
Pages: 341-360
ISSN: 0065-3411 (ISSN-L)
DOI: 10.1016/j.yasu.2011.04.003
PMC: PMC3578602
OpenAlex: W2141463948
Cited by: 81
References: 79
Citations by year: 2025: 2 · 2022: 3 · 2021: 5 · 2020: 10 · 2019: 6 · 2018: 3 · 2017: 2 · 2016: 9 · 2015: 9 · 2014: 2 · 2013: 14 · 2012: 16
FWCI: 0.94
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Advances in Surgery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01SC003811)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, metastatic solid tumors, metastatic melanoma, renal cell carcinoma, interleukin-2, anti-CTLA-4, adoptive T cell therapy, tumor-infiltrating lymphocytes, lymphocyte depletion, cancer vaccines, tumor-associated antigens, chimeric antigen receptor T cells, combination therapy
MeSH terms: Ipilimumab, Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Cytotoxicity, Immunologic, Genetic Engineering, Humans, Immunotherapy, Melanoma, Neoplasm Metastasis, Receptors, Antigen, T-Cell, Skin Neoplasms, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Adoptive Transfer, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunotherapy for metastatic solid cancers

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks